Revenue
$12.26B
Gross Margin
+86.3%
Operating Margin
+39.0%
Net Margin
+35.4%
Income statement waterfall for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026
Net income: $4.34B
Margin breakdown for Vertex Pharmaceuticals (VRTX) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $12.26B | $12.26B |
| Cost of Revenue | −$1.68B | $10.57B |
| Gross Profit | $10.57B | $10.57B |
| Operating Expenses | −$5.80B | $4.78B |
| Operating Income | $4.78B | $4.78B |
| Other Income / Expense | $389.90M | $5.17B |
| Pre-tax Income | $5.17B | $5.17B |
| Income Tax | −$827.40M | $4.34B |
| Net Income | $4.34B | $4.34B |
- Revenue$12.26B
- Cost of Revenue−$1.68B
- Gross Profit$10.57B
- Operating Expenses−$5.80B
- Operating Income$4.78B
- Other Income / Expense$389.90M
- Pre-tax Income$5.17B
- Income Tax−$827.40M
- Net Income$4.34B
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement